Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019, at 11:15 a.m. EDT. The conference will be held at the InterContinental New York Barclay Hotel in New York City.

Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that new clinical data on cosibelimab (formerly CK-301), a potentially differentiated high affinity anti-PD-L1 antibody with functional Fc domain, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 - October 1, 2019, in Barcelona, Spain. The poster presentation will provide updated interim results from Checkpoint’s ongoing multicenter Phase 1 clinical trial, including safety and efficacy data on additional patients and longer follow-up periods from the expansion cohorts. Checkpoint continues to enroll patients into potential registration-enabling cohorts in order to support one or more marketing application submissions based on this ongoing clinical trial.

Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

NEW YORK, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that James F. Oliviero, President and Chief Executive Officer, will participate in three investor conferences in September 2019.

Checkpoint Therapeutics to Present at September 2019 Investor Conferences

Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Checkpoint Therapeutics, Inc. (CKPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

News for Checkpoint Therapeutics Stock (CKPT)